LG Chem and Merck Biopharma Korea said Monday the two firms agreed to sell Rovatitan (ingredient: rosuvastatin, valsartan) jointly, a treatment for hypertension and dyslipidemia.
In April 2015, the two companies concluded a contract for sales and marketing of Rovatitan, with Merck Biopharma Korea in charge of distribution and sales.
The latest agreement allows LG Chem to distribute Rovatitan to hospitals and clinics with 300 sickbeds or less, and the two together sell the drug to general hospitals with more than 300 sickbeds.
Rovatitan is a fixed-dose combination therapy, developed by LG Chem. The treatment combines valsartan, an angiotensin II receptor blocker, and rosuvastatin, a statin-based agent.
“Rovatitan pills are single-layer tablets containing both rosuvastatin and valsartan evenly. The tablet is small so that it raises patient compliance,” said Kim Young-cheol in charge of Rovatitan marketing at LG Chem’s life sciences business division. “We have released six kinds of combinations out of rosuvastatin 5mg, 10, 20mg and valsartan 80mg and 160 mg. This combo drug makes it easier to control doses.”
The two companies are expected to enhance marketing for Rovatitan through the strategic partnership and secure more competitiveness in the combo drug market for hypertension and dyslipidemia.